MedinCell (ENXTPA:MEDCL) Wins FDA Approval For WELTRUZA, Is The Stock Fully Priced?

The U.S. FDA approval of WELTRUZA, an olanzapine long-acting injectable, sits at the center of MedinCell (ENXTPA:MEDCL) right now, with management scheduling a special call to unpack the implications.

The share price reaction has been sharp, with MedinCell up 16.89% on a 1-day share price return and 30.90% over 7 days, as investors weigh the FDA approval of WELTRUZA against a more measured 5.90% 1-year total shareholder return and a very large 3-year total shareholder gain that suggests longer term momentum has already been strong.

Scan beyond MedinCell and see how other potential breakout candidates in similar territory stack up in our hand-picked 127 healthcare AI stocks .

After a jump like this on WELTRUZA's approval, the real puzzle is whether MedinCell's valuation still leaves meaningful upside on the table or if the bulk of the move already happened this week.

Most Popular Narrative: 17% Undervalued

On the widely followed narrative, MedinCell's fair value of €35.07 sits above the last close at €29.06. This puts the WELTRUZA move against a backdrop of already modelled upside and execution risk.

The diversification of the BEPO technology platform into new high-growth therapeutic areas (contraception, oncology, CNS) and transition of multiple partnered and in-house programs toward clinical stages is set to drive future revenue streams and stabilize earnings as the company moves beyond reliance on its initial blockbusters.

See why 6 investors see MedinCell as 17% undervalued .

Result: Fair Value of €35.07 (UNDERVALUED)

Still, MedinCell's heavy dependence on UZEDY and olanzapine LAI, along with its loss of €31.287 million on €24.277 million of revenue, keeps execution risk front and center.

Find out about the key risks to this MedinCell narrative .

Another View on MedinCell's Valuation

The earlier narrative leaned on fair value estimates and future earnings assumptions to argue MedinCell looks undervalued. A simple revenue multiple tells a very different story. At a P/S of 43x against a European pharmaceuticals average of 3.9x and a fair ratio of 8.7x, the stock screens as richly priced on current sales, which raises the question of how much execution risk you are really comfortable carrying.

To see how that revenue multiple fits into a fuller picture of MedinCell, including what the numbers imply for pricing risk, check the See what the numbers say about this price — find out in our valuation breakdown. .

Next Steps

Plenty in this MedinCell story can feel conflicting, so move fast, dig into the underlying data, and weigh the 3 key rewards and 1 important warning sign .